Bent Jakobsen

Bent Jakobsen is the Founder and Chief Executive Officer at Accession Therapeutics Limited and has held various influential roles in the biotechnology sector. They served as Chief Scientific Officer and later Chief Scientific Advisor at Adaptimmune Therapeutics PLC, which they co-founded in 2008 to develop cancer therapeutics using T cell receptor technology. Their expertise also includes significant positions at Immunocore Limited, where they contributed to the development of the first TCR therapeutic to gain market approval. Additionally, Bent is a current Board Member at several companies, including Zelluna Immunotherapy AS and Nextera AS, reflecting their continued influence in the field of therapeutic innovations. They earned their Doctor of Philosophy degree in Biochemistry and Molecular Biology from Aarhus University.